15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Sanofi ADR, 3 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $58.00 to $58.00, so the covering firms are broadly aligned. The average target of $58.00 sits 27% above the current $45.52. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.60 next quarter toward $5.14 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Hold
Strong Buy00%
Buy343%
Hold457%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Sanofi ADR.
As of Jul, 3 of 7 firms rate SNY a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SNY EPS & revenue forecast
EPS · NEXT QUARTER
$1.60
Range $1.60 – $1.60 · 1 analysts · -6% YoY
Next period, 1 analysts expect Sanofi ADR to earn $1.60 a share (range $1.60 – $1.60), versus $1.69 a year earlier. Full-year consensus is $4.79, growing to $5.14 the year after.
REVENUE · NEXT QUARTER
$13.4B
Range $13.3B – $13.7B · 1 analysts · +8% YoY
Revenue is expected to reach $13.4B (range $13.3B – $13.7B), +7.6% year-over-year. Full-year consensus is $46.9B, rising to $50.0B next year.
Top analysts covering Sanofi ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNY.
#1
Seamus Fernandez
Guggenheim
Hold
No targeton SNY
Coverage
—
+ Follow
#2
RV
Richard Vosser
JP Morgan
Hold
No targeton SNY
Coverage
—
+ Follow
#3
JQ
James Quigley
Goldman Sachs
Hold
$60.00+31.8% to target
Coverage
—
+ Follow
#4
MW
Matthew Weston
UBS
Hold
No targeton SNY
Coverage
—
+ Follow
#5
EF
Emily Field
Barclays
Hold
No targeton SNY
Coverage
—
+ Follow
SNY stock forecast FAQ
What is SNY's average 12-month price target?+
The 1 analysts with a live target average $58.00 for Sanofi ADR over the next 12 months, ranging from a $58.00 high to a $58.00 low.
Is SNY stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 7 analyst ratings, 3 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover SNY?+
7 analysts have an active rating on Sanofi ADR, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering SNY?+
Among analysts who currently cover SNY, Seamus Fernandez of Guggenheim has the strongest overall Quantellect track record. Their current call is Hold.
What is Sanofi ADR's projected EPS for next quarter?+
The consensus estimate is $1.60 per share (range $1.60 – $1.60) across 1 analysts. Full-year EPS is projected at $4.79, rising to $5.14 the following year.
How much revenue is Sanofi ADR expected to report next quarter?+
Consensus revenue is $13.4B (range $13.3B – $13.7B). Full-year revenue is projected at $46.9B, growing to $50.0B next year.
Have analysts been upgrading or downgrading SNY lately?+
As of Jul, 3 of 7 firms rate SNY a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
